Inhibikase Therapeutics
IKT
12 hedge funds and large institutions have $444K invested in Inhibikase Therapeutics in 2024 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 5 reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
47% more capital invested
Capital invested by funds: $301K → $444K (+$143K)
9% more funds holding
Funds holding: 11 → 12 (+1)
0.52% less ownership
Funds ownership: 3.84% → 3.32% (-0.52%)
60% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$49.9K |
| 2 |
William Blair & Company
Chicago,
Illinois
|
+$36K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$7.09K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
+$4.41K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$13 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$144K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$6.95K |
| 3 |
Renaissance Technologies
New York
|
-$6.62K |
| 4 |
Morgan Stanley
New York
|
-$3.68K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
William Blair & Company
Chicago,
Illinois
| $165K | +$36K | +16,333 | +27% |
|
2
Geode Capital Management
Boston,
Massachusetts
| $62K | – | – | – |
|
|
3
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $48.9K | +$49.9K | +22,616 | New |
|
|
4
Renaissance Technologies
New York
| $46K | -$6.62K | -3,000 | -12% |
|
|
RAM
5
Redmond Asset Management
Henrico,
Virginia
| $42.3K | -$185 | -84 | -0.4% |
|
|
6
Vanguard Group
Malvern,
Pennsylvania
| $36.1K | -$144K | -65,321 | -80% |
|
7
State Street
Boston,
Massachusetts
| $21.8K | – | – | – |
|
|
8
UBS Group
Zurich,
Switzerland
| $6.94K | +$7.09K | +3,214 | New |
|
|
TRCT
9
Tower Research Capital (TRC)
New York
| $5.99K | -$6.95K | -3,148 | -53% |
|
|
10
Osaic Holdings
Scottsdale,
Arizona
| $4.32K | +$4.41K | +2,000 | New |
|
|
11
Morgan Stanley
New York
| $3.6K | -$3.68K | -1,667 | -50% |
|
|
12
Wells Fargo
San Francisco,
California
| $447 | +$13 | +6 | +3% |
|
|
13
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$3K | -2,000 | Closed |
|
14
Bank of America
Charlotte,
North Carolina
| – | -$79 | -62 | Closed |
|
IKT Hedge Fund Activity: Q1 2024 in Review
12 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Inhibikase Therapeutics (IKT) for Q1 2024, worth a combined $444K — up 47% from $301K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new IKT positions and 2 closed out — a net gain of 1 holder — while 2 added to existing stakes and 5 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $49.9K. The largest seller was Vanguard Group, cutting an estimated $144K.
- 12 institutional investors held Inhibikase Therapeutics (IKT) as of Q1 2024, up from 11 in Q4 2023.
- Funds reported $444K of Inhibikase Therapeutics stock for Q1 2024, up 47% quarter-over-quarter.
- 3 funds opened new Inhibikase Therapeutics positions in Q1 2024 and 2 closed out, a net change of +1 holder.
- The largest Inhibikase Therapeutics buyer in Q1 2024 was Susquehanna International Group, an estimated $49.9K added.
- The largest Inhibikase Therapeutics seller in Q1 2024 was Vanguard Group, an estimated $144K sold.
Based on aggregated 13F filings for Q1 2024.